NightHawk Biosciences (NHWK) Stock Price, News & Analysis

Company Overview

NightHawk Biosciences, Inc., an integrated biopharmaceutical company, develops, manufactures, and commercializes medical countermeasures that combat unmet and emerging biothreats. The company develops ANTHIM (obiltoxaximab), a monoclonal antibody antitoxin for the treatment of inhalational anthrax. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.26 to $0.50
• 52-Week Range: N/A
• Volume: 173,100 shs
• Average Volume: 97,242 shs
• Market Capitalization: $10.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NHWK Stock Analysis - Frequently Asked Questions

How were NightHawk Biosciences' earnings last quarter?

NightHawk Biosciences, Inc. (NYSE:NHWK) issued its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.01. The biopharmaceutical company had revenue of $0.50 million for the quarter, compared to analysts' expectations of $0.57 million. NightHawk Biosciences had a negative trailing twelve-month return on equity of 91.62% and a negative net margin of 2,333.27%.

When did NightHawk Biosciences' stock split?

NightHawk Biosciences shares reverse split on Friday, December 11th 2020. The 1-7 reverse split was announced on Thursday, December 10th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 11th 2020. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of NightHawk Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NightHawk Biosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Meta Platforms (META), Vaxart (VXRT), Alibaba Group (BABA), NVIDIA (NVDA) and Novavax (NVAX).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 4/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NYSE:NHWK
• CIK: 1476963
• Web: www.nighthawkbio.com
• Phone: 919-240-7133
• Fax: N/A
• Employees: 77
• Year Founded: 2008

Profitability

• EPS (Most Recent Fiscal Year): ($1.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-43,440,000.00
• Net Margins: -2,333.27%
• Pretax Margin: -2,546.97%
• Return on Equity: -91.62%
• Return on Assets: -56.48%

Debt

• Debt-to-Equity Ratio: 0.27
• Current Ratio: 0.99
• Quick Ratio: 0.99

Sales & Book Value

• Annual Sales: $6.38 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.82 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 26,080,000
• Free Float: 21,935,000
• Market Cap: $10.78 million
• Optionable: Optionable
• Beta: 0.19